Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

INM Relative to the S&P 500

INM Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the InMed Pharmaceuticals Inc. (NASD:INM) seasonal charts above shows that a Buy Date of November 12 and a Sell Date of February 2 has resulted in a geometric average return of 24.55% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 124.55% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. It operates through the InMed Pharma and BayMedica Commercial segments. The InMed Pharma segment focuses on research and development. The BayMedica Commercial segment refers to manufacturing technologies to produce and commercialize bulk cannabinoids for sale as ingredients in the health and wellness industry. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

To download INM seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: INM